As targeted therapies are becoming more common on the market and prescribed by physicians, it is necessary to develop strategies to support patients with this new treatment modality. Auto-injectors require patients to administer their own medication. While they can be time and cost-effective, less than 50% of patients continue to adhere to their treatment after six months. A study conducted in 2019 found that medication non-adherence costs are estimated to be between $100 to $290 billion in the United States and approximately 1.25 billion € in Europe annually. In this article, we break down the self-administration process into three phases, each with specific end goals.
"*" indicates required fields